Notify me when BVF PARTNERS L P/IL files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| MLTX | MoonLake Immunotherapeutics | Class A ordinary share, par value $0.0001 per share | 28% | $141,616,706 | 19,751,284 | BVF PARTNERS L P/IL | 06 Nov 2025 | ||
| RPTX | Repare Therapeutics Inc. | Common Shares, no par value | 24% | $18,497,144 | 10,333,600 | BVF PARTNERS L P/IL | 20 Nov 2025 | ||
| KYMR | Kymera Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 8.5% | $450,459,592 | 6,867,809 | BVF PARTNERS L P/IL | 11 Dec 2025 | ||
| IVA | Inventiva S.A. | Ordinary Shares, nominal value (euro)0.01 per share | 5% | $39,714,931 | +$4,251,111 | 9,569,863 | +12% | BVF PARTNERS L P/IL | 17 Nov 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|